Mar 25 |
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
|
Mar 18 |
Avenue Therapeutics GAAP EPS of -$0.98 misses by $0.01
|
Mar 18 |
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
|
Mar 15 |
Avenue Therapeutics granted extension for Nasdaq compliance
|
Mar 15 |
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
|
Mar 11 |
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
|
Mar 11 |
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
|
Feb 22 |
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
|
Jan 24 |
Avenue Therapeutics files to sell 33.08M shares of common stock for holders
|
Jan 16 |
Sidoti Events, LLC's Virtual January Micro-Cap Conference
|